Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
APLS Stock Chart & Stats
$20.53
-$1.37(-3.96%)
At close: 4:00 PM EST
$20.53
-$1.37(-3.96%)
Day’s Range― - ―
52-Week Range$16.10 - $31.17
Previous CloseN/A
Volume215.04K
Average Volume (3M)2.58M
Market Cap
$2.60B
Enterprise Value$2.94B
Total Cash (Recent Filing)$479.17M
Total Debt (Recent Filing)$475.37M
Price to Earnings (P/E)67.2
Beta0.95
Next Earnings
Mar 04, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.67
Shares Outstanding126,525,215
10 Day Avg. Volume3,276,650
30 Day Avg. Volume2,579,419
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)17.30
Price to Sales (P/S)5.06
P/FCF Ratio-44.79
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue2.89
Enterprise Value/Gross Profit3.26
Enterprise Value/Ebitda31.47
Forecast
1Y Price Target
$35.38Price Target Upside72.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
EPS Forecast (FY)-1.09
Revenue Forecast (FY)$859.72M
Bulls Say, Bears Say
Bulls Say
Empaveli Launch MomentumAnalyst notes Empaveli's launch in rare kidney diseases such as C3G and IC‑MPGN is outpacing expectations with rapid U.S. market penetration supported by broad payer coverage and a favorable label, indicating potential to become the standard of care.
Financial Runway And FundingReported cash balances are assessed as sufficient to fund the company toward profitability, lowering near‑term financing risk and supporting ongoing development and commercialization plans.
Syfovre Market Position And Administration ImprovementsAnalyst highlights Syfovre's sustained leadership in geographic atrophy and a planned prefilled syringe filing alongside an imaging tool initiative that could increase physician adoption and strengthen competitive position.
Bears Say
Co‑pay Assistance ConstraintsAnalyst warns persistent co‑pay funding shortages are limiting patient access and creating a sales headwind that curtails Syfovre revenue and conversion of demand into product sales.
Regulatory And Profitability RiskAnalyst flags the company's ongoing lack of profitability and regulatory uncertainty for pursued indications as key risks that could constrain adoption and valuation if clinical or approval setbacks occur.
Weak Volume And Growth MomentumAnalyst reports Syfovre exhibited flat or declining injection volumes versus prior periods, prompting lowered revenue estimates and signaling pressure on growth momentum.
Apellis Pharmaceuticals News
APLS FAQ
What was Apellis Pharmaceuticals Inc’s price range in the past 12 months?
Apellis Pharmaceuticals Inc lowest stock price was $16.10 and its highest was $31.17 in the past 12 months.
What is Apellis Pharmaceuticals Inc’s market cap?
Apellis Pharmaceuticals Inc’s market cap is $2.60B.
When is Apellis Pharmaceuticals Inc’s upcoming earnings report date?
Apellis Pharmaceuticals Inc’s upcoming earnings report date is Mar 04, 2026 which is in 45 days.
How were Apellis Pharmaceuticals Inc’s earnings last quarter?
Apellis Pharmaceuticals Inc released its earnings results on Oct 30, 2025. The company reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.579 by $0.091.
Is Apellis Pharmaceuticals Inc overvalued?
According to Wall Street analysts Apellis Pharmaceuticals Inc’s price is currently Undervalued.
Does Apellis Pharmaceuticals Inc pay dividends?
Apellis Pharmaceuticals Inc does not currently pay dividends.
What is Apellis Pharmaceuticals Inc’s EPS estimate?
Apellis Pharmaceuticals Inc’s EPS estimate is -0.39.
How many shares outstanding does Apellis Pharmaceuticals Inc have?
Apellis Pharmaceuticals Inc has 126,525,215 shares outstanding.
What happened to Apellis Pharmaceuticals Inc’s price movement after its last earnings report?
Apellis Pharmaceuticals Inc reported an EPS of $1.67 in its last earnings report, beating expectations of $1.579. Following the earnings report the stock price went down -31.015%.
Which hedge fund is a major shareholder of Apellis Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in APLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Apellis Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.38 (72.33% Upside)
$35.38 (72.33% Upside)
Blogger Sentiment
Neutral
APLS Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 17.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $607.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.0%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-29.28%
12-Months-Change
Fundamentals
Return on Equity
14.10%
Trailing 12-Months
Asset Growth
17.39%
Trailing 12-Months
Company Description
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
APLS Company Deck
APLS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected significant progress with the FDA approval of EMPAVELI and strong market leadership of SYFOVRE. However, challenges in SYFOVRE revenue due to free drug programs and operational challenges in patient access were notable concerns.View all APLS earnings summariesAPLS Stock 12 Month Forecast
Average Price Target
$35.38
▲(72.33% Upside)
Technical Analysis
Zai Lab
―
Crinetics Pharmaceuticals
―
―
Mirum Pharmaceuticals
―
MoonLake Immunotherapeutics
―
Ownership Overview
3.88% Insiders
20.42% Mutual Funds
0.09% Other Institutional Investors
61.16% Public Companies and Individual Investors